既存の潰瘍性大腸炎は,免疫関連大腸炎のリスクを高め,免疫チェックポイント阻害剤で治療された胃腸がん患者の生存結果が異なることを予測します
Shuo Xu1, Lu Chen1, Kaixuan Liu2
1Department of Gastroenterology and Hepatology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Frontiers in immunology
|August 29, 2025
まとめ
免疫チェックポイント阻害剤 (ICI) を服用している潰瘍性大腸炎 (UC) の患者は,免疫関連大腸炎 (IRC) のリスクが高くなります. 軽度のIRCは より良い結果と相関し 厳しいIRCは 慎重に管理する必要があります
科学分野:
- 腫瘍学
- 胃腸内科
- 免疫学
背景:
- 免疫チェックポイント阻害剤 (ICI) 治療を受けている胃腸がんと既発性潰瘍性大腸炎 (UC) の患者における免疫関連大腸炎 (IRC) の発生率と臨床的影響は十分に確立されていません.
- このリスクを理解することは 治療戦略と患者の結果の最適化に不可欠です
研究 の 目的:
- 胃腸がんのICIで治療された既存のUC患者におけるIRCのリスクを調査する.
- この患者集団におけるIRCに関連する臨床効果と生存結果を評価する.
主な方法:
- 2021年1月から2024年5月の間にICIを受けた胃腸がんおよびUC患者の電子医療記録の遡及レビュー.
- IRCの発生率の比較
- COX回帰を用いた無進行生存率 (PFS) と全生存率 (OS) を含む生存分析.
主要な成果:
- 既存のUCを有する31人の患者のうち71%がIRCを発症し,半数以上が重度のIRCを発症し,UCのない患者よりも著しく高い割合 (17. 4%) であった.
- 軽度のIRCの患者は,IRCのない患者と比較してPFS (170 vs 96日) とOS (261 vs 172日) が改善した.
- 深刻なIRCはPFSの利点を提供した (147 vs 96日) が,OSの有意な違いはなかった. 軽度のIRCは好ましい予後因子であった (HR=0. 286),重度のIRCはそうではなかった (HR=1. 149).
- IRC患者では血清のIL- 6およびIL- 17A濃度が上昇した.
結論:
- 既存のUCの患者は,ICIで治療された場合,IRCのリスクが高くなります.
- 軽度のIRCは好ましい予後を示し,重度のIRCの警戒管理が臨床上の利益を最大化することの重要性を強調する.
- IL-6経路をターゲットにすることは,将来的にIRCを管理するための潜在的な治療戦略です.
さらに関連する動画
関連する概念動画
Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Inflammatory Bowel Disease II: Crohn's Disease
375
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
375
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
413
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
413
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659


